72 related articles for article (PubMed ID: 12962368)
1. Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study.
Tsitsilonis OE; Tsavaris NB; Kosmas C; Gouveris P; Papalambros E
J Chemother; 2003 Aug; 15(4):387-93. PubMed ID: 12962368
[TBL] [Abstract][Full Text] [Related]
2. The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
Tsavaris NB; Katsoulas HL; Kosmas C; Papalambros E; Gouveris P; Papantoniou N; Rokana S; Kosmas N; Skopeliti M; Tsitsilonis OE
Oncology; 2004; 67(5-6):403-10. PubMed ID: 15713997
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.
Baxevanis CN; Tsavaris NB; Papadhimitriou SI; Zarkadis IK; Papadopoulos NG; Bastounis EA; Papamichail M
Eur J Cancer; 1997 Jul; 33(8):1202-8. PubMed ID: 9301443
[TBL] [Abstract][Full Text] [Related]
4. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.
Masucci G; Wersäll P; Nielsen J; Nielsen HK; Wigzell H; Mellstedt H
Hybridoma; 1989 Oct; 8(5):507-16. PubMed ID: 2807310
[TBL] [Abstract][Full Text] [Related]
6. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
7. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
8. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
[TBL] [Abstract][Full Text] [Related]
9. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
10. Low-doses of sequential-kinetic-activated interferon-γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study.
Radice E; Miranda V; Bellone G
Int Immunopharmacol; 2014 Mar; 19(1):66-73. PubMed ID: 24369312
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
12. Anti-candidial activity of natural killer (NK) and lymphokine activated killer (LAK) lymphocytes in vitro.
Gülay Z; Imir T
Immunobiology; 1996 Jul; 195(2):220-30. PubMed ID: 8877398
[TBL] [Abstract][Full Text] [Related]
13. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
14. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
[TBL] [Abstract][Full Text] [Related]
16. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
17. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
